BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 25267660)

  • 1. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.
    Boisson M; Jacobs M; Grégoire N; Gobin P; Marchand S; Couet W; Mimoz O
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7331-9. PubMed ID: 25267660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.
    Grégoire N; Mimoz O; Mégarbane B; Comets E; Chatelier D; Lasocki S; Gauzit R; Balayn D; Gobin P; Marchand S; Couet W
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7324-30. PubMed ID: 25267662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients.
    Boisson M; Grégoire N; Cormier M; Gobin P; Marchand S; Couet W; Mimoz O
    J Antimicrob Chemother; 2017 Sep; 72(9):2607-2612. PubMed ID: 28575278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.
    Landersdorfer CB; Nguyen TH; Lieu LT; Nguyen G; Bischof RJ; Meeusen EN; Li J; Nation RL; McIntosh MP
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.
    Jacobs M; Grégoire N; Mégarbane B; Gobin P; Balayn D; Marchand S; Mimoz O; Couet W
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1788-93. PubMed ID: 26729492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.
    Imberti R; Cusato M; Villani P; Carnevale L; Iotti GA; Langer M; Regazzi M
    Chest; 2010 Dec; 138(6):1333-9. PubMed ID: 20558557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.
    Plachouras D; Karvanen M; Friberg LE; Papadomichelakis E; Antoniadou A; Tsangaris I; Karaiskos I; Poulakou G; Kontopidou F; Armaganidis A; Cars O; Giamarellou H
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3430-6. PubMed ID: 19433570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
    Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing of colistin-back to basic PK/PD.
    Bergen PJ; Li J; Nation RL
    Curr Opin Pharmacol; 2011 Oct; 11(5):464-9. PubMed ID: 21835694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic analysis of colistin in burn patients.
    Lee J; Han S; Jeon S; Hong T; Song W; Woo H; Yim DS
    Antimicrob Agents Chemother; 2013 May; 57(5):2141-6. PubMed ID: 23439640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome.
    Ram K; Sheikh S; Bhati RK; Tripathi CD; Suri JC; Meshram GG
    Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):128-140. PubMed ID: 33245629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review.
    Heffernan AJ; Sime FB; Lipman J; Dhanani J; Andrews K; Ellwood D; Grimwood K; Roberts JA
    Int J Antimicrob Agents; 2019 Mar; 53(3):234-245. PubMed ID: 30472292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection.
    Karnik ND; Sridharan K; Jadhav SP; Kadam PP; Naidu RK; Namjoshi RD; Gupta V; Gore MS; Surase PV; Mehta PR; Gogtay JA; Thatte UM; Gogtay NJ
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1429-36. PubMed ID: 23508665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of diluent volume of colistimethate sodium on aerosol characteristics and pharmacokinetics in ventilator-associated pneumonia caused by MDR bacteria.
    Bihan K; Zahr N; Becquemin MH; Lu X; Bertholon JF; Vezinet C; Arbelot C; Monsel A; Rouby JJ; Langeron O; Lu Q
    J Antimicrob Chemother; 2018 Jun; 73(6):1639-1646. PubMed ID: 29506194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study.
    Moni M; Sudhir AS; Dipu TS; Mohamed Z; Prabhu BP; Edathadathil F; Balachandran S; Singh SK; Prasanna P; Menon VP; Patel T; Patel P; Kaye KS; Menon VP
    Int J Infect Dis; 2020 Nov; 100():497-506. PubMed ID: 32781161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou QT; Cheah SE; Zhao J; Chen K; Wang J; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
    Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
    Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.
    Mohamed AF; Karaiskos I; Plachouras D; Karvanen M; Pontikis K; Jansson B; Papadomichelakis E; Antoniadou A; Giamarellou H; Armaganidis A; Cars O; Friberg LE
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4241-9. PubMed ID: 22615285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.
    Garonzik SM; Li J; Thamlikitkul V; Paterson DL; Shoham S; Jacob J; Silveira FP; Forrest A; Nation RL
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3284-94. PubMed ID: 21555763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration.
    Karvanen M; Plachouras D; Friberg LE; Paramythiotou E; Papadomichelakis E; Karaiskos I; Tsangaris I; Armaganidis A; Cars O; Giamarellou H
    Antimicrob Agents Chemother; 2013 Jan; 57(1):668-71. PubMed ID: 23147733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.